Accelerated Approval and Rare Disease Therapy

Accelerated approval is central to how modern rare disease therapies reach patients. It is also one of the most contested topics in regulatory science. This post explains what accelerated approval is, why it exists, and what it actually means for families.

What accelerated approval is

Accelerated approval is a regulatory pathway that allows a drug to reach the market based on early evidence, often using a surrogate endpoint that is reasonably likely to predict clinical benefit. The drug is approved with the understanding that confirmatory studies will continue and that the approval can be revised if those studies do not support the early signal.

In the United States, accelerated approval is governed by FDA regulations and is used for serious or life-threatening conditions where there is an unmet medical need. Similar pathways exist in the European Union under the term conditional marketing authorisation.

Why it exists

Some diseases progress faster than traditional clinical trials can be completed. In Duchenne muscular dystrophy, ambulatory function can change meaningfully in a year. Waiting a decade for definitive long-term data, while clinically valuable, can mean that a generation of patients never gets the chance to benefit.

Accelerated pathways were designed to address that tension. They allow patients to access promising therapies earlier, while the evidence base continues to be built.

What can go wrong

Early evidence is not always confirmed. A drug approved on accelerated grounds may later show smaller benefits than hoped, unexpected risks, or both.

In DMD, the FDA approval of Elevidys (delandistrogene moxeparvovec) is a useful example. The drug was initially approved on the basis of micro-dystrophin expression. The label expanded in 2024 to a broader patient group, then was revised again with a boxed warning after reports of fatal acute liver failure in non-ambulatory patients. (FDA, safety warning and revised indication for Elevidys)

In the European Union, the EMA recommended non-renewal of the conditional authorisation for Translarna (ataluren) for nonsense-mutation DMD, concluding that effectiveness had not been confirmed. (EMA on Translarna non-renewal)

These are not failures of the pathway. They are the pathway working as designed, sometimes painfully.

What this means for families

Accelerated approval is not a promise of long-term benefit. It is a permission to begin treatment under continued evaluation.

Practical questions families can ask: Is this approval accelerated or traditional? What is the surrogate endpoint, and what is its relationship to function? When is the confirmatory data expected? What happens to access if the data is inconclusive?

Care teams should be able to address each of these, with current information.

Cost in the accelerated pathway

Accelerated approval does not lower the price of treatment. Specialty drugs and gene therapies approved through accelerated pathways often carry the highest prices in modern medicine. Payers and governments still need to decide whether and how to fund therapies under continuing evaluation.

For background, see DMD treatment cost and health technology assessment in rare disease.

Trust and the public conversation

Accelerated approvals can become flashpoints in public debate. Patient advocates argue that delay equals harm. Critics argue that early access without firm benefit data risks both patients and payers. Both positions can be honest.

What helps the conversation is transparency about evidence, clear post-approval monitoring, and clean separation between scientific scrutiny and political agendas.

For more on this, see regulatory trust in rare disease.

What is still uncertain

The right balance between speed and certainty is not settled. Different regulators reach different conclusions for the same therapy. Different countries fund different subsets of approved drugs.

The reasonable framing is that accelerated approval is a tool, not a verdict. It is most useful when families, clinicians, regulators, and payers all use it with their eyes open.

For related reading, see Elevidys explained, gene therapy for Duchenne, and the reported piece Duchenne, drug approval, and public policy.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.